CDH12 and glioblastoma: Moreover, bladder cancer patients rich in CDH12 had excellent responses to immune checkpoint therapy, providing strong evidence for the design of biomarker guided clinical trials.[112] In addition, spatial metabolomics and spatial proteomics combined with SRT analysis elucidate the tumor‐host cell interaction, and well reveal the spatio‐temporal alterations of transcriptional heterogeneity and regional hypoxia metabolism in glioblastoma (GBM).